Bibliography
- Bohm M, Reil JC, Deedwania P, et al. Resting heart rate: risk indicator and emerging risk factor in cardiovascular disease. Am J Med 2015;128:219-28
- Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014;371:1091-9
- Cocco G, Jerie P. Torsdes de pointes induced by the concomitant use of ivabradine and azithromycin. an unespected dangerous intreraction. Cardiovasc Toxicol 15(1):104-6
- Frishman WH. beta-adrenergic blockade in cardiovascular disease. J Cardiovasc Pharmacol Ther 2013;18:310-19
- Riccioni G. Ivabradine: the hope for a good treatment of ischemic heart disease. Curr Med Chem 2013;20:1817-23
- Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807-16
- Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-85
- Teerlink JR. Ivabradine in heart failure—non paradign SHIFT…yet. Lancet 2010;376:847-9
- Cocco G, Jerie P. Comparison between ivabradine and low-dose digoxin in the therapy of diastolic heart failure with preserved left ventricular systolic function. Clin Pract 2013;3(2):e29
- Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 2008;29(10):1327-34